Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2007, Article ID 91586, 6 pages
http://dx.doi.org/10.1155/2007/91586
Case Report

Osteomalacia as a Late Metabolic Complication of Ifosfamide Chemotherapy in Young Adults: Illustrative Cases and Review of the Literature

1Department of Medical Oncology, Bristol Haematology and Oncology Centre, Horfield Road, Bristol BS2 8ED, UK
2Department of Cellular & Molecular Medicine, School of Medical Sciences, University of Bristol, Bristol BS8 1TD, UK
3Richard Bright Kidney Unit, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK
4Department of Radiology, Bristol Royal Infirmary, Marlborough Street, Bristol BS2 8HW, UK

Received 22 August 2006; Accepted 7 March 2007

Academic Editor: Penella Woll

Copyright © 2007 D. N. Church et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. H. C. Bramwell, H. T. Mouridsen, A. Santoro et al., “Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas,” European Journal of Cancer and Clinical Oncology, vol. 23, no. 3, pp. 311–321, 1987. View at Publisher · View at Google Scholar
  2. K. H. Antman, L. Ryan, A. Elias, D. Sherman, and H. E. Grier, “Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma,” Journal of Clinical Oncology, vol. 7, no. 1, pp. 126–131, 1989. View at Google Scholar
  3. S. R. Patel, S. Vadhan-Raj, M. A. Burgess et al., “Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas,” American Journal of Clinical Oncology, vol. 21, no. 3, pp. 317–321, 1998. View at Publisher · View at Google Scholar
  4. P. Bruhl, H. Hoefer-Janker, W. Scheef, and W. Vahlensieck, “Prophylactic alkalization of the urine during cytostatic tumor treatment with the oxazaphosphorine derivatives, cyclophosphamide and ifosfamide,” Onkologie, vol. 2, no. 3, pp. 120–124, 1979. View at Google Scholar
  5. W. Scheef, H. O. Klein, N. Brock et al., “Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results,” Cancer Treatment Reports, vol. 63, no. 3, pp. 501–505, 1979. View at Google Scholar
  6. R. Skinner, “Chronic ifosfamide nephrotoxicity in children,” Medical and Pediatric Oncology, vol. 41, no. 3, pp. 190–197, 2003. View at Publisher · View at Google Scholar
  7. R. Skinner, I. M. Sharkey, A. D. J. Pearson, and A. W. Craft, “Ifosfamide, mesna, and nephrotoxicity in children,” Journal of Clinical Oncology, vol. 11, no. 1, pp. 173–190, 1993. View at Google Scholar
  8. J. W. Foreman and K. S. Roth, “Human renal Fanconi syndrome—then and now,” Nephron, vol. 51, no. 3, pp. 301–306, 1989. View at Google Scholar
  9. D. W. Cockcroft and M. H. Gault, “Prediction of creatinine clearance from serum creatinine,” Nephron, vol. 16, no. 1, pp. 31–41, 1976. View at Google Scholar
  10. S. J. Strauss, A. McTiernan, D. Driver et al., “Single center experience of a new intensive induction therapy for ewing's family of tumors: feasibility, toxicity, and stem cell mobilization properties,” Journal of Clinical Oncology, vol. 21, no. 15, pp. 2974–2981, 2003. View at Publisher · View at Google Scholar
  11. C. B. Pratt, W. H. Meyer, J. J. Jenkins et al., “Ifosfamide, Fanconi's syndrome, and rickets,” Journal of Clinical Oncology, vol. 9, no. 8, pp. 1495–1499, 1991. View at Google Scholar
  12. M. S. Ashraf, J. Brady, F. Breatnach, P. F. Deasy, and A. O'Meara, “Ifosfamide nephrotoxicity in paediatric cancer patients,” European Journal of Pediatrics, vol. 153, no. 2, pp. 90–94, 1994. View at Publisher · View at Google Scholar
  13. R. Rossi, A. Godde, A. Kleinebrand et al., “Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients,” Journal of Clinical Oncology, vol. 12, no. 1, pp. 159–165, 1994. View at Google Scholar
  14. R. Skinner, S. J. Cotterill, and M. C. G. Stevens, “Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group,” British Journal of Cancer, vol. 82, no. 10, pp. 1636–1645, 2000. View at Publisher · View at Google Scholar
  15. F. Marinez, G. Deray, P. Cacoub, H. Beaufils, and C. Jacobs, “Ifosfamide nephrotoxicity: deleterious effect of previous cisplatin administration,” The Lancet, vol. 348, no. 9034, pp. 1100–1101, 1996. View at Publisher · View at Google Scholar
  16. R. Rossi, A. Godde, A. Kleinebrand, B. Rath, and H. Jurgens, “Concentrating capacity in ifosfamide-induced severe renal dysfunction,” Renal Failure, vol. 17, no. 5, pp. 551–557, 1995. View at Google Scholar
  17. R. Skinner, A. D. J. Pearson, M. W. English et al., “Risk factors for ifosfamide nephrotoxicity in children,” The Lancet, vol. 348, no. 9027, pp. 578–580, 1996. View at Publisher · View at Google Scholar
  18. M. J. Zamlauski-Tucker, M. E. Morris, and J. E. Springate, “Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney,” Toxicology and Applied Pharmacology, vol. 129, no. 1, pp. 170–175, 1994. View at Publisher · View at Google Scholar
  19. M. Mohrmann, S. Ansorge, U. Schmich, B. Schonfeld, and M. Brandis, “Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture,” Pediatric Nephrology, vol. 8, no. 2, pp. 157–163, 1994. View at Publisher · View at Google Scholar
  20. J. E. Springate, “Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo,” Journal of Applied Toxicology, vol. 17, no. 1, pp. 75–79, 1997. View at Publisher · View at Google Scholar
  21. L. Dubourg, C. Michoudet, P. Cochat, and G. Baverel, “Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide,” Journal of the American Society of Nephrology, vol. 12, no. 8, pp. 1615–1623, 2001. View at Google Scholar
  22. M. Mohrmann, S. Ansorge, B. Schonfeld, and M. Brandis, “Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells,” Pediatric Nephrology, vol. 8, no. 4, pp. 458–465, 1994. View at Publisher · View at Google Scholar
  23. C. D. Burk, I. Restaino, B. S. Kaplan, and A. T. Meadows, “Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilms tumor,” Journal of Pediatrics, vol. 117, no. 2 part 1, pp. 331–335, 1990. View at Google Scholar
  24. A. Suarez, H. McDowell, P. Niaudet, E. Comoy, and F. Flamant, “Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report,” Journal of Clinical Oncology, vol. 9, no. 12, pp. 2177–2182, 1991. View at Google Scholar
  25. R. Loebstein and G. Koren, “Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors,” Pediatrics, vol. 101, no. 6, p. E8, 1998. View at Publisher · View at Google Scholar
  26. N. M. Marina, C. A. Poquette, A. M. Cain, D. Jones, C. B. Pratt, and W. H. Meyer, “Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas,” Journal of Pediatric Hematology/Oncology, vol. 22, no. 2, pp. 112–118, 2000. View at Publisher · View at Google Scholar
  27. R. Skinner, A. D. J. Pearson, L. Price, M. G. Coulthard, and A. W. Craft, “Nephrotoxicity after ifosfamide,” Archives of Disease in Childhood, vol. 65, no. 7, pp. 732–738, 1990. View at Google Scholar
  28. R. Rossi, A. Kleinbrand, A. Godde, B. Rath, and H. Jurgens, “Increased risk of ifosfamide-induced renal Fanconi's syndrome after unilateral nephrectomy,” The Lancet, vol. 341, no. 8847, p. 755, 1993. View at Publisher · View at Google Scholar
  29. A. V. Boddy, M. English, A. D. J. Pearson, J. R. Idle, and R. Skinner, “Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics,” European Journal of Cancer—Part A, vol. 32, no. 7, pp. 1179–1184, 1996. View at Publisher · View at Google Scholar
  30. R. Rossi, P. Schafers, J. Pleyer, C. Postler, J. Boos, and H. Jurgens, “The influence of short versus continuous ifosfamide infusion on the development of renal tubular impairment,” International Journal of Pediatric Hematology/Oncology, vol. 4, no. 4, pp. 393–399, 1997. View at Google Scholar
  31. R. M. Rossi, C. Kist, U. Wurster, W.-R. Kulpmann, and J. H. H. Ehrich, “Estimation of ifosfamide/cisplatinum-induced renal toxicity by urinary protein analysis,” Pediatric Nephrology, vol. 8, no. 2, pp. 151–156, 1994. View at Publisher · View at Google Scholar
  32. J. Z. Melnick, M. Baum, and J. R. Thompson, “Aminoglycoside-induced Fanconi's syndrome,” American Journal of Kidney Diseases, vol. 23, no. 1, pp. 118–122, 1994. View at Google Scholar
  33. H. N. Caron, N. Abeling, A. van Gennip, J. de Kraker, and P. A. Voucte, “Hyperaminoaciduria identifies patients at risk of developing renal tubular toxicity associated with ifosfamide and platinate containing regimens,” Medical and Pediatric Oncology, vol. 20, no. 1, pp. 42–47, 1992. View at Publisher · View at Google Scholar
  34. R. Rossi, “Nephrotoxicity of ifosfamide—moving towards understanding the molecular mechanisms,” Nephrology Dialysis Transplantation, vol. 12, no. 6, pp. 1091–1092, 1997. View at Google Scholar
  35. S. van Gool, P. Brock, G. Wijndaele et al., “Reversible hypophosphatemic rickets following ifosfamide treatment,” Medical and Pediatric Oncology, vol. 20, no. 3, pp. 254–257, 1992. View at Publisher · View at Google Scholar
  36. V. K. Prasad, I. J. Lewis, S. R. Aparicio et al., “Progressive glomerular toxicity of ifosfamide in children,” Medical and Pediatric Oncology, vol. 27, no. 3, pp. 149–155, 1996. View at Publisher · View at Google Scholar
  37. A. A. Garcia, “Ifosfamide-induced Fanconi syndrome,” Annals of Pharmacotherapy, vol. 29, no. 6, pp. 590–591, 1995. View at Google Scholar
  38. A. Negro, G. Regolisti, F. Perazzoli, S. Davoli, C. Sani, and E. Rossi, “Ifosfamide-induced renal Fanconi syndrome with associated nephrogenic diabetes insipidus in an adult patient,” Nephrology Dialysis Transplantation, vol. 13, no. 6, pp. 1547–1549, 1998. View at Publisher · View at Google Scholar
  39. C. Beckwith, K. K. Flaharty, A. K. Cheung, and P. G. Beatty, “Fanconi's syndrome due to ifosfamide,” Bone Marrow Transplantation, vol. 11, no. 1, pp. 71–73, 1993. View at Google Scholar
  40. L. Duck, J.-P. Devogelaer, A. Persu et al., “Osteomalacia due to chemotherapy-induced Fanconi syndrome in an adult patient,” Gynecologic Oncology, vol. 98, no. 2, pp. 329–331, 2005. View at Publisher · View at Google Scholar
  41. R. Skinner, A. D. J. Pearson, M. G. Coulthard et al., “Assessment of chemotherpy-associated nephrotoxicity in children with cancer,” Cancer Chemotherapy and Pharmacology, vol. 28, no. 2, pp. 81–92, 1991. View at Publisher · View at Google Scholar
  42. M. Rehling, M. L. Moller, B. Thamdrup et al., “Simultaneous measurement of renal clearance and plasma clearance of T99mc-labelled diethylenetriaminepenta-acetate, C51r-labelled ethylenediaminetetra-acetate and inulin in man,” Clinical Science, vol. 66, no. 5, pp. 613–619, 1984. View at Google Scholar
  43. E. Berman, M. Nicolaides, R. G. Maki et al., “Altered bone and mineral metabolism in patients receiving imatinib mesylate,” New England Journal of Medicine, vol. 354, no. 19, pp. 2006–2013, 2006. View at Google Scholar